Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Value Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B), while Vanguard Value Index Fund ETF trades at $219.98 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 3.4× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| REGN | VTV | |
|---|---|---|
Market Cap | $76.40B | $262.40B |
Volume | 626,381 | 3,955,043 |
Sector | Health | — |
52-Week High | $852.03 | $227.51 |
52-Week Low | $557.73 | $182.86 |
Typical Hold Time | 107 Days | 142 Days |
Enterprise Value | $71.12B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
VTV trades at $218.21, down 0.35% on the day, with a bearish technical signal driven by moving averages. The ETF's 2.3% dividend yield and low 0.03% expense ratio appeal to income-focused investors. Recent news highlights value stocks outperforming growth in 2026, with institutional buying from firms like QRG Capital Management.
The outlook for VTV is mixed; value rotation tailwinds and solid yield support income strategies, but technical weakness and long-term underperformance versus the S&P 500 pose risks. Investors should weigh its defensive value exposure against broader market momentum shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
